International Stem Cell (ISCO) EV to EBIT (2010 - 2026)

International Stem Cell (ISCO) has reported EV to EBIT for 17 consecutive years, with 12.34 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to EBIT fell 671.24% year-over-year to 12.34 in Q2 2026; TTM through Jun 2026 was 4.96, a 19.72% decrease from a year earlier, with the FY2025 full-year figure at 0.48, down 105.51% from the prior year.
• EV to EBIT was 12.34 for Q2 2026 at International Stem Cell, down from 0.41 in the prior quarter.
• Over five years, EV to EBIT peaked at 248.9 in Q1 2023 and troughed at 12.34 in Q2 2026.
• A 5-year average of 27.95 and a median of 2.37 in 2023 frame the typical range for EV to EBIT.
• Across the five-year window, EV to EBIT jumped 1880.73% in 2022 and slumped 671.24% in 2026, its largest moves.
• Over 5 years, EV to EBIT stood at 11.46 in 2022, then tumbled by 77.19% to 2.61 in 2023, then slumped by 542.54% to 11.56 in 2024, then soared by 96.47% to 0.41 in 2025, then slumped by 2926.17% to 12.34 in 2026.
• The last three EV to EBIT figures came in at 12.34 (Q2 2026), 0.41 (Q4 2025), and 0.79 (Q3 2025), per Business Quant data.